Improvements in fasting glucose, HbA1c, and insulin sensitivity measures further validate semaglutide’s efficacy and safety as a treatment option for obesity-associated prediabetes [22]. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.